title: Long-term results of dose density therapy in patients with aggressive lymphoma.
abstract: To evaluate the long-term outcome of dose density chemotherapy in the treatment of aggressive lymphoma, we analyzed 142 patients with untreated aggressive lymphoma. Chemotherapy was an eight-drug regimen given in weekly intervals in two prospective trials. The median observation period was 8 years; the longest follow-up was 13 years. Overall survival at 8 years was 0.583. The 8-year survival of patients < or =60 years was significantly better than that of older patients, namely 0.713 vs 0.304 (p=0.000000697). This excellent survival of patients aged < or =60 years was identical for high-risk and high-intermediate-risk patients compared with low-risk and low-intermediate-risk patients in the age-adjusted international prognostic index (IPI). The excellent long-term results of the CEOP/IMVP-Dexa regimen (cyclophosphamide, epirubicin, vincristine, and prednisone/ifosfamide with systemic mesna, methotrexate, etoposide, and dexamethasone) for patients aged < or =60 years suggest that this regimen might be superior to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and needs to be tested in comparison to high-dose regimens and novel approaches including antibody treatment.
authors.affiliation: Department of Oncology, AKH Linz, Linz 4020, Austria. michael.fridrik@akh.linz.at
authors.forename: Michael A
authors.initials: MA
authors.lastname: Fridrik
authors.forename: Hubert
authors.initials: H
authors.lastname: Hausmaninger
authors.forename: Werner
authors.initials: W
authors.lastname: Linkesch
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
authors.forename: Otto
authors.initials: O
authors.lastname: Krieger
authors.forename: Christian
authors.initials: C
authors.lastname: Baldinger
authors.forename: Joerg
authors.initials: J
authors.lastname: Klocker
authors.forename: Joerg
authors.initials: J
authors.lastname: Pont
authors.forename: Willhelm
authors.initials: W
authors.lastname: Oberaigner
mesh_terms: D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002423:Cause of Death; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008137:Longitudinal Studies; D008223:Lymphoma / Q000188:drug therapy*; D015080:Mesna / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate